Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Invested Capital (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Invested Capital for 4 consecutive years, with $208.3 million as the latest value for Q4 2025.

  • Quarterly Invested Capital fell 12.12% to $208.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $208.3 million through Dec 2025, down 12.12% year-over-year, with the annual reading at $208.3 million for FY2025, 12.12% down from the prior year.
  • Invested Capital hit $208.3 million in Q4 2025 for Axsome Therapeutics, up from $193.7 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $458.8 million in Q2 2023 to a low of $64.7 million in Q1 2022.
  • Historically, Invested Capital has averaged $251.1 million across 4 years, with a median of $235.1 million in 2024.
  • Biggest five-year swings in Invested Capital: surged 316.34% in 2023 and later tumbled 61.54% in 2024.
  • Year by year, Invested Capital stood at $204.6 million in 2022, then soared by 81.36% to $371.0 million in 2023, then plummeted by 36.11% to $237.0 million in 2024, then fell by 12.12% to $208.3 million in 2025.
  • Business Quant data shows Invested Capital for AXSM at $208.3 million in Q4 2025, $193.7 million in Q3 2025, and $193.1 million in Q2 2025.